Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate
نویسندگان
چکیده
منابع مشابه
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
PURPOSE To determine the clinical significance of molecular response and relapse among patients with chronic myelogenous leukemia (CML) treated with imatinib. EXPERIMENTAL DESIGN We analyzed the results of quantitative PCR in 280 patients with CML in chronic phase who achieved complete cytogenetic remission with imatinib (117 after IFN-alpha failure and 163 previously untreated). Median follo...
متن کاملDevelopment of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
PURPOSE Infection with Varicella-Zoster virus (VZV) is an exceptionally rare complication of chronic myelogenous leukemia (CML) without stem cell transplantation. We report 16 patients with CML who developed VZV infection during imatinib mesylate therapy. PATIENTS AND METHODS From July 1998 until February 2002, 771 patients were included in 11 imatinib mesylate studies for all CML phases in t...
متن کاملPregnancy Outcome of Two Patients with Chronic Myelogenous Leukemia Treated with Imatinib
Although chronic myelogenous leukemia in pregnancy is rare, its management and treatment is more difficult and complicated.Treatment of patients with chronic myelogenous leukemia includes bone marrow transplantation, however in less than 30% of patients the donor’s organ would be accepted. To this end, cytotoxic therapy is considered as an alternative therapeutic option. This option provides sa...
متن کاملHematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
Imatinib mesylate, an Abl kinase inhibitor, produces sustained complete hematologic responses (CHRs) in chronic myelogenous leukemia (CML) patients, but the sequence and timing of morphologic and cytogenetic changes in CML patients during prolonged imatinib mesylate treatment has not been described. In this report, we document sequential hematologic and bone marrow findings in 19 interferon-ref...
متن کاملSuccessful childbirth in a patient with chronic myelogenous leukemia treated with imatinib mesylate during early pregnancy.
AIMS To report a case of successful pregnancy in a patient with chronic myelogenous leukemia treated with imatinib mesylate for the first 4 months of pregnancy. RESULTS Imatinib mesylate is potentially teratogenic and its use during pregnancy in humans can lead to abortion or development of fetal abnormalities in nearly 40% of fully reported cases. We report a case of a 28-year-old woman who ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2003
ISSN: 0007-1048
DOI: 10.1046/j.1365-2141.2003.04208_3.x